#### LAMPERT MARK N

Form 4 June 01, 2018

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**OMB APPROVAL OMB** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

burden hours per

response...

Estimated average

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Middle)

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* **BVF PARTNERS L P/IL** 

(First)

(Street)

2. Issuer Name and Ticker or Trading

Symbol

ARQULE INC [ARQL]

3. Date of Earliest Transaction (Month/Day/Year)

05/30/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

Director

\_X\_\_ 10% Owner Other (specify Officer (give title

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Applicable Line)

Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting

Person

below)

Issuer

### SAN FRANCISCO, CA 94104

1 SANSOME ST, 30TH FL

(City)	(State)	(Zip) Tak	ole I - Non-	-Derivative S	Securi	ties Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed 3. 4. Securities Acquired (A) Execution Date, if Transactiomr Disposed of (D) any Code (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock, \$0.01 par value per share (1)	05/30/2018		Code V	Amount 547,860	(D)	Price \$ 5.0001	4,682,669	D (2)	
Common Stock, \$0.01 par value per share (1)	05/30/2018		S	312,266	D	\$ 5.0001	3,186,044	D (3)	
Common Stock,	05/30/2018		S	175,813	D	\$ 5.0001	771,305	D (4)	

\$0.01 par value per share (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	\$ 1.75 <u>(5)</u>					<u>(5)</u>	10/11/2021	Common Stock, \$0.01 par value per share	1,201,053
Warrants	\$ 1.75 <u>(5)</u>					<u>(5)</u>	10/11/2021	Common Stock, \$0.01 par value per share	823,231
Warrants	\$ 1.75 <u>(5)</u>					<u>(5)</u>	10/11/2021	Common Stock, \$0.01 par value per share	199,687

## **Reporting Owners**

Reporting Owner Name / Address	Relationship				
	Director	10% Owner	Officer	Other	
BVF PARTNERS L P/IL		X			
1 SANSOME ST					

Reporting Owners 2

#### Edgar Filing: LAMPERT MARK N - Form 4

30TH FL

SAN FRANCISCO, CA 94104

BIOTECHNOLOGY VALUE FUND L P

1 SANSOME ST

30TH FL See Explanation of Responses

SAN FRANCISCO, CA 94104

BIOTECHNOLOGY VALUE FUND II LP

1 SANSOME ST

30TH FL See Explanation of Responses

SAN FRANCISCO, CA 94104

Biotechnology Value Trading Fund OS LP

P.O. BOX 309 UGLAND HOUSE See Explanation of Responses

GRAND CAYMAN, E9 KY1-1104

BVF Partners OS Ltd.

P.O. BOX 309 UGLAND HOUSE See Explanation of Responses

GRAND CAYMAN, E9 KY1-1104

**BVF INC/IL** 

1 SANSOME ST

30TH FL

SAN FRANCISCO, CA 94104

LAMPERT MARK N

1 SANSOME ST 30TH FL

BVF Inc., By: /s/ Mark N. Lampert, President

SAN FRANCISCO, CA 94104

### **Signatures**

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President					
**Signature of Reporting Person	Date				
Biotechnology Value Fund, L.P., By: BVF Partners L.P., its general partner, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/01/2018				
**Signature of Reporting Person	Date				
Biotechnology Value Fund II, L.P., By: BVF Partners L.P., its general partner, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/01/2018				
**Signature of Reporting Person	Date				
BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/01/2018				
**Signature of Reporting Person					
<b>—</b> • • • • • • • • • • • • • • • • • • •	Date				
Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	Date 06/01/2018				
Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager,					

Signatures 3

\*\*Signature of Reporting Person

06/01/2018

Date

/s/ Mark N. Lampert 06/01/2018

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and
- (1) Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  - Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners
- (4) OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- The Warrants are currently exercisable, for \$1.75 per share, subject to adjustment pursuant to the terms of the Warrants and expire on October 11, 2021. The Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.9% of the shares of Common Stock outstanding immediately after giving effect to such exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.